Compare Becton Dickinson and Co (BDX) vs Freeport-McMoRan Inc (FCX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs Freeport-McMoRan Inc — how do they compare? Becton Dickinson and Co trades at $182.62 (market cap $50.00B), while Freeport-McMoRan Inc trades at $67.82 (market cap $96.91B). The key difference: Freeport-McMoRan Inc is the larger of the two by market cap, and Becton Dickinson and Co pays the higher dividend (2.29%). Which is the better fit depends on your goals.
| BDX | FCX | |
|---|---|---|
Market Cap | $50.00B | $96.91B |
Sector | Health | Basic Materials |
52-Week High | $185.39 | $71.73 |
52-Week Low | $138.62 | $35.34 |
Enterprise Value | $66.10B | $103.19B |
Dividend Yield | 2.29% | 0.87% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX trades at $183.71, up 2.27% today, near its consensus price target of $183.00. The stock shows bullish technical signals with strong moving averages, though RSI indicates overbought conditions. Fundamentally, revenue grew to $21.84 billion in 2025, with consistent earnings beats in recent quarters, including Q3 2026 EPS of $3.23 beating estimates. The company maintains a dividend of $1.05 per share and recently raised full-year guidance, reflecting operational strength amid tariff pressures.
Outlook remains positive with raised profit guidance and segment growth, but risks include margin pressure from tariffs and a product recall. Analyst sentiment is mixed with 47% buy ratings, suggesting cautious optimism. The stock offers stability as a Dividend Aristocrat with growth catalysts from medical technology advancements, though investors should monitor margin trends and competitive dynamics.
FCX trades at $69.23, down 1.84% on the day, with a bullish technical signal supported by moving averages and strong support at $68. The company reported Q2 2026 EPS of $0.68, beating estimates, and maintains robust cash flow from operations of $5.61 billion in 2025. Recent news highlights growth from Grasberg ramp-up and copper market tailwinds.
Outlook is positive with a consensus price target of $73.85, reflecting 6.7% upside, driven by earnings beats and expansion projects. Risks include commodity price volatility and execution challenges at new mines. Analyst sentiment is strongly bullish with 61% buy ratings, but overbought RSI levels suggest near-term caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About Freeport-McMoRan Inc
Freeport-McMoRan Inc is an international mining company. It operates geographically diverse assets with proven and probable mineral reserves of copper, gold and molybdenum. The company's portfolio of assets includes the Grasberg minerals district in Indonesia
Read more on FCX →
